Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region.
Probst, G.D., Bowers, S., Sealy, J.M., Stupi, B., Dressen, D., Jagodzinska, B.M., Aquino, J., Gailunas, A., Truong, A.P., Tso, L., Xu, Y.Z., Hom, R.K., John, V., Tung, J.S., Pleiss, M.A., Tucker, J.A., Konradi, A.W., Sham, H.L., Jagodzinski, J., Toth, G., Brecht, E., Yao, N., Pan, H., Lin, M., Artis, D.R., Ruslim, L., Bova, M.P., Sinha, S., Yednock, T.A., Gauby, S., Zmolek, W., Quinn, K.P., Sauer, J.M.(2010) Bioorg Med Chem Lett 20: 6034-6039
- PubMed: 20822903 
- DOI: https://doi.org/10.1016/j.bmcl.2010.08.070
- Primary Citation of Related Structures:  
3NSH - PubMed Abstract: 
The structure-activity relationship of the prime region of hydroxyethylamine BACE inhibitors is described. Variation in the aryl linker region with 5- and 6-membered heterocycles provided compounds such as 33 with improved permeability and reduced P-gp liability compared to benzyl amine analog 1.
Organizational Affiliation: 
Department of Medicinal Chemistry, Elan Pharmaceuticals, South San Francisco, CA 94080, USA.